Velodyne Lidar With Kaarta Cloud Can Produce Stunning 3D Maps
Velodyne Lidar, Inc. today announced Kaarta Cloud ® exclusively supports Velodyne’s lidar sensors. Kaarta’s new cloud-based application is a platform to process, store, and share 3D spaces. Paired with high quality lidar to capture the environment in 3D, the data is uploaded into Kaarta Cloud to quickly and easily process it into a point cloud for use. High quality 3D mobile mapping is now available to a broader consumer base.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200818005149/en/
The Kaarta Cloud® platform allows users to process Velodyne’s 3D lidar data into a registered point cloud map. It provides a continuous framework to the data which then can be optimized with functions including filtering, loop closure, conversion and more. (Photo: Kaarta)
Three Velodyne sensors – Ultra Puck™, Puck™ and HDL-32E – are supported by Kaarta Cloud. After using a Velodyne sensor to scan the environment, Kaarta’s proprietary Kaarta Engine uses simultaneous localization and mapping (SLAM) algorithms to instantaneously process lidar data into a registered point cloud map. This enables users to produce accurate, measurable 3D models and vivid visual representations of complex environments, ranging from buildings and infrastructure to dangerous and hard-to-reach areas.
Mobile scanning systems are continually advancing and the possibilities for use are expansive. There is growing interest in lidar imaging for post-earthquake assessment, surveys of damaged buildings, aiding first responders in emergency situations and more. As the applications and sophistication of these tools grow, so does the size and complexity of the data collected, necessitating new ways of managing massive data sets that can be in excess of one billion points. To do so, Kaarta Cloud uses an ultra-high performance parallel-processed network to handle the processing of massive reality capture files. Kaarta Cloud workflow is designed to optimize operations, extract the maximum value from lidar scans, and facilitate data sharing and collaboration through its secure cloud storage platform.
Kaarta Cloud supports all of Kaarta’s robust mobile mapping systems which integrate Velodyne’s Puck, HDL-32E and Ultra Puck into Kaarta’s Stencil 2-16, Stencil 2-32 and Stencil Pro, respectively. Velodyne and Kaarta have strong experience in helping customers address mapping challenges in a wide variety of applications. For instance, Allvision and the City of Pittsburgh used a Velodyne-powered Kaarta solution to conduct detailed curb and parking analysis. This project provided information to help develop efficient and equitable urban mobility, enable quicker deliveries and significantly improve public parking experiences. Another example is McVeigh & Mangum Engineering, which used a Velodyne-powered Kaarta solution in a highly challenging initiative to document a North Carolina hospital with digital mapping.
Customers can now register for a 30-day free trial of the new Kaarta Cloud platform. Kaarta, as an Automated with Velodyne partner, will discuss how companies can use Velodyne’s lidar integration with Kaarta Cloud during a joint webinar on August 21, from 10:00 to 10:45 a.m. PDT.
“Kaarta Cloud opens up access to Kaarta’s advanced SLAM-based technology to Velodyne’s lidar sensors, in addition to Kaarta systems,” said Kevin Dowling, CEO, Kaarta. “It provides a fast, flexible workflow to manage mobile mapping 3D data from field capture to finished data.”
“Kaarta Cloud is an exciting innovation for the growing ecosystem of software tools that allow Velodyne’s lidar customers and partners to produce awesome 3D digital twins,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Online SLAM processing of lidar data expands the capabilities, scope, ease of use and speed at which the user community can leverage Velodyne’s sensors. This will help unlock the tremendous potential for lidar-based innovation and mapping applications.”
Velodyne Ultra Puck, Puck and HDL-32E sensors deliver a high resolution image to measure and analyze a variety of environments. They provide high quality resolution and performance along with a full 360-degree environmental view to deliver real-time 3D data.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
Kaarta, an innovator of real-time mobile 3D reality capture, transforms the real world into its digital twin with speed, fidelity and ease. Kaarta’s patent-pending technology, rooted in advanced robotics, is a fast track from capture to answer, streamlining workflow, reducing time, lowering cost and providing a new level of understanding of spaces for humans and autonomous machines alike. Now the spectrum of stakeholders across AECO, facilities planners and managers, natural resource management professionals and mobile robotics developers can work from the same framework. Additional information is available at www.kaarta.com.
Landis Communications Inc.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom